Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET, FILM COATED
**4.2 Posology and method of administration** **Posology** Oral use. The dose is one tablet of 35 mg of trimetazidine twice daily i.e. once in the morning and once in the evening during meals. The benefit of the treatment should be assessed after three months and trimetazidine should be discontinued if there is no treatment response. **Special populations** _Patients with renal impairment_ In patients with moderate renal impairment (creatinine clearance \[30–60\] ml/min) (see sections 4.4 and 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), the recommended dose is 1 tablet of 35 mg in the morning during breakfast. _Elderly patients_ Elderly patients may have increased trimetazidine exposure due to age-related decrease in renal function (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). In patients with moderate renal impairment (creatinine clearance \[30–60\] ml/min), the recommended dose is 1 tablet of 35 mg in the morning during breakfast. Dose titration in elderly patients should be exercised with caution (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Paediatric population:_ The safety and efficacy of trimetazidine in children aged below 18 years have not been established. No data are available.
ORAL
Medical Information
**4.1 Therapeutic indications** Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders. Severe renal impairment (creatinine clearance < 30ml/min).
Pending
xpending
Manufacturer Information
SERVIER (S) PTE LTD
LES LABORATOIRES SERVIER INDUSTRIE
Kotra Pharma (M) Sdn Bhd
Active Ingredients
Documents
Package Inserts
Vastarel MR Tablet 35mg PI.pdf
Approved: July 6, 2021